Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well lower doses of bortezomib,
dexamethasone, and cyclophosphamide work in treating older patients with multiple myeloma.
Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing. Giving cyclophosphamide daily may kill more cancer cells. Giving
bortezomib, cyclophosphamide, and dexamethasone may be an effective treatment for multiple
myeloma.